Clinical trials: Platinum-sensitive Relapsed Primary Peritoneal Cancer
Platinum-sensitive Relapsed Epithelial Ovarian Cancer, Platinum-sensitive Relapsed Fallopian Tube Cancer
Torvutatug Samrotecan With or Without Bevacizumab as Maintenance Treatment of Platinum-sensitive Relapsed Epithelial Ovarian Cancer
The purpose of this study is to measure the efficacy and safety of torvutatug samrotecan (torvu-sam) with or without bevacizumab compared to standard of care (SoC) as maintenance treatment in participants with platinum-sensitive…
- Conditions
- Platinum-sensitive Relapsed Epithelial Ovarian Cancer, Platinum-sensitive Relapsed Fallopian Tube Cancer, Platinum-sensitive Relapsed Primary Peritoneal Cancer
- Trial name
- TREVI-OC-03 (NCT07816666)
- Testing
- Torvutatug samrotecan, Bevacizumab
- Where
- 124 sites in United States, Australia and 11 more
- Volunteers
- 600 people
- Sponsor
- AstraZeneca
Ovarian Cancer, Epithelial Ovarian Cancer
A Study of Rucaparib in Patients With Platinum-Sensitive, Relapsed, High-Grade Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (ARIEL2)
The purpose of this study is to determine which patients with ovarian, fallopian tube, and primary peritoneal cancer will best respond to treatment with rucaparib.
- Conditions
- Ovarian Cancer, Epithelial Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Cancer
- Trial name
- ARIEL2 (NCT01891344)
- Testing
- Oral rucaparib
- Where
- 75 sites in United States, Australia and 4 more
- Volunteers
- 491 people
- Sponsor
- pharmaand GmbH
Ovarian Neoplasms, Peritoneal Neoplasms
BIBF 1120 + Carboplatin/Pegylated Liposomal Doxorubicin (PLD) in Patients With Advanced Ovarian Cancer, Fallopian Tube Carcinoma or Primary Peritoneal Cancer
This phase I, open label dose escalation study will investigate the addition of BIBF 1120 to treatment with the combination of carboplatin and Pegylated Liposomal Doxorubicin (PLD) in patients with advanced, platinum sensitive…
- Trial name
- NCT01314105
- Testing
- BIBF 1120 + PLD 30 mg/m2 + CBDCA AUC5 mg/mL*min, BIBF 1120+ PLD 30 mg/m2 + CBDCA AUC5 mg/mL*min
- Where
- 3 sites in Spain
- Volunteers
- 19 people
- Sponsor
- Boehringer Ingelheim